NewAmsterdam Pharma
Clinical trials sponsored by NewAmsterdam Pharma, explained in plain language.
A biopharmaceutical company developing therapies for cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers sought to test if experimental drug boosts antioxidant absorption. Results expected Sep 2026 (estimated) May already have reported ↗
- New combo aims to crush 'Bad' cholesterol particle that other drugs miss Results expected Nov 2026 (estimated)
-
New daily pill aims to crush stubborn cholesterol in High-Risk patients
Disease control CompletedThis Phase 3 trial tested a daily pill combining two drugs, obicetrapib and ezetimibe, in 407 people with inherited high cholesterol or heart disease. Participants took the combination or a placebo on top of their usual cholesterol meds. The main goal was to see if the combo lowe…
Phase 3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill could help lower stubborn high cholesterol
Disease control CompletedThis study tested a new drug called obicetrapib in over 2,500 people with high cholesterol that wasn't well controlled by their current treatments. Participants took either a 10 mg obicetrapib pill or a placebo daily for about 6 months. The main goal was to see if obicetrapib cou…
Phase 3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 26, 2026 18:50 UTC